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Abstract. Prostate cancer is a leading cause of cancer death among men. Currently available screening test measures prostate-
specific antigen (PSA) to detect prostate cancer. However, this test produces false positive values that often lead to negative
biopsies. Therefore, a more reliable diagnostic tool is needed. Glycans in serum are of particular interest as around half of all
proteins are glycosylated. In this study, N-linked glycans were enzymatically released by PNGase F from prostate epithelial cell
lines (pRNS) expressing wild type or mutant androgen receptors and a small set of human serum samples. Released glycans were
purified and partitioned into neutral and acidic components by solid phase extraction (SPE) using graphitized carbon cartridges.
The SPE fractions were analyzed by matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass
spectrometry (MALDI FT-ICR MS). Significant changes in some high-mannose and fucosylated biantennary complex N-linked
glycans were observed in the serum of prostate cancer patients.
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1. Introduction
Prostate cancer is the second leading cause of cancer
death and the most frequently diagnosed cancer among
men. In 2007, the estimated number of deaths and new
cases in the US alone are 27,050 and 218,890, respec-
tively [1]. Although the exact cause of prostate cancer
is still unknown, several risk factors are associated with
it, including age, race, family history, and diet [1]. Un-
fortunately, the common symptoms of prostate cancer
are not specific to the disease and early stage may show
no noticeable symptoms. Early diagnosis is important
because prostate cancer may be more easily and suc-
∗Corresponding author. Tel.: +1 530 752 6364; Fax: +1 530 752
8995; E-mail: cblebrilla@ucdavis.edu.
cessfully treated when detected early. It is estimated
that if the cancer is diagnosed at localized stages, 100%
of men will survive longer than five years. At distant
stages, however, only 33% will survive longer than five
years [1,2].
Currently, the prostate specific antigen (PSA) is re-
garded as the best tumor marker for prostate cancer [2–
4]. PSA is a glycoprotein that helps in the liquefaction
of the semen. A PSA concentration below 4 ng/mL
in the serum implies the absence of cancer, since the
release of PSA in the bloodstream of healthy individu-
als is unlikely. However, there are instances when the
membrane of the prostate epithelial cells is disrupted
which leads to the disproportionate leaking of PSA in-
to the bloodstream. Moreover, an enlargement of the
prostate is known to affect PSA levels. Thus, there
ISSN 0278-0240/08/$17.00  2008 – IOS Press and the authors. All rights reserved
244 M.L.A. de Leoz et al. / Glycomic approach for potential biomarkers on prostate cancer
may be an increase in serum PSA levels not only in
prostate cancer, but also in benign prostate diseases
such as benign prostatic hyperplasia (BPH) and phys-
ical trauma of the prostate. An increase in the serum
PSA levels, therefore, is indicative of pathologies of the
prostate gland, but PSA may not be a specific marker
for prostate cancer [4,5]. Thus, PSA oftentimes gives
false positive values that may lead to unnecessary biop-
sies. Approximately 60–80% of PSA-driven prostate
biopsies are negative [2,4]. A more alarming concern
is the reported 20% incidence of false negatives in the
low PSA levels, i.e. in the range of 2.5–4 ng/mL [6].
Clearly, a more sensitive and specific diagnostic tool
for prostate cancer is needed.
Recently, the percent free PSA, which is the ratio
of free PSA to total PSA, is being explored as a more
reliable screening test for prostate cancer than PSA.
This test improves sensitivity to 90–95%, consequently
reducing the number of unneeded biopsies to 15–20%.
Other PSA tests that are examined include PSA density,
PSA velocity, percent complex PSA, and new molecu-
lar forms of PSA such as proPSA, BPSA, ‘intact’ PSA,
PSA-A2M and PSA-API [2,4,5,7].
Other biomarkers aside from PSA have also been
studied. For example, Bondar et al. have looked at
Zn-α2 glycoprotein (ZAG) as a potential biomarker for
prostate cancer [8]. They quantified a unique peptide
by subjecting ZAG to proteolytic cleavage followed
by liquid chromatography and tandem mass spectrom-
etry (LC-MS/MS) analysis. Another potential pro-
tein biomarker for prostate cancer is α-methylacyl-
coenzyme-A racemase (AMACR) [9]. Maraldo et
al. quantified AMACR from urine without sample
preparation using a macrocantilever-based technique.
Thus, biomarkers associated with the presence of
prostate cancer have been extensively studied using
electrophoresis, protein expression, tissue microar-
rays, macrocantilevers, tandem mass spectrometry (LC
MS/MS), matrix-assisted laser desorption ionization
(MALDI) and surface enhanced laser desorption ion-
ization (SELDI)-mass spectrometry (MS) [10–13], but
these potential biomarkers still need to undergo valida-
tion before acceptance in the clinical laboratory.
Changes in glycosylation have been implicated in
many diseases including cancer [14–18]. Glycosyla-
tion, whether N-linked or O-linked, is highly sensitive
to the biochemical environment and is the most com-
mon post-translational modification of proteins on the
cell surface and in the extracellular matrix [19–21].
The biosynthesis of oligosaccharides relies on a num-
ber of highly competitive processes, suggesting that the
concentration of specific glycosyl transferases is highly
variable and could yield completely different products.
Because of this, monitoring changes in glycosylation
may prove to be a more specific and sensitive method
for biomarker discovery and disease diagnosis.
Studies have been made in our laboratory regarding
O-linked glycans, i.e. glycans attached to the serine
(Ser) or threonine (Thr) residue of the protein. For ovar-
ian cancer, fifteen possible O-linked glycan markers
were found in patient sera that were not found in normal
sera [16,22]. We also analyzed several breast cancer
tumor cell lines and patient sera for possible breast can-
cer “glycan signatures” [23]. In all cases, the O-linked
glycans were released by β-elimination and analyzed
by matrix-assisted laser desorption/ionization Fourier
transform ion cyclotron resonance (MALDI FT-ICR)
mass spectrometry and infrared multiphoton dissocia-
tion (IRMPD). In these studies, some glycan masses
were found that were derived from N-linked glycans
that could have been produced by cross-ring cleavage
from the sodium borohydride treatment.
We analyzed the N-linked glycans in prostate epithe-
lial cells and human sera in this present study. The
N-linked glycans are of particular interest since they
are more abundant in human sera than O-linked gly-
cans [19]. In N-glycosylation, the glycan is attached to
the asparagine (Asn) residue of the protein in the con-
sensus sequence Asn-Xaa-Ser/Thr (Xaa = any amino
acid except proline (Pro)). Changes in the degree of
branching and levels of sialylation and fucosylation in
N-linked glycans have been reported as a consequence
of diseases. Novotny and co-workers recently showed
that the N-linked glycans of the prostate cancer patients
increased in total fucosylation while the glycans of the
healthy individuals had a slight increase in mannosyla-
tion [24]. Tabares et al. [3] showed a decrease in the
fucose and α2,3-linked sialic acid content of PSA in
the patient human serum. They also established differ-
ences in glycosylation between the PSAs of the prostate
cancer serum and prostate metastatic tumor cell line
LNCaP, which may imply that cell lines do not suf-
ficiently represent the physiological environment. In
another recent study, glycosylation of haptoglobin in
human sera was found to have enhanced branching, sia-
lylation and fucosylation in individuals with prostate
cancer [25].
Profiles of N-linked glycans isolated from the im-
mortalized pRNS prostate epithelial cell lines (pRNS)
that express wild type or mutant androgen receptors
were prepared. Moreover, profiles of N-linked glycans
isolated from human sera were obtained from control
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and patient groups. The control group is composed of
individuals with low PSA values (< 0.1 ng/mL) who
had undergone radical retropubic prostatectomy while
the patient group had individuals with elevated PSA
values (5.4–27.0 ng/mL) on active surveillance. The
profiles of the two groups were then statistically com-
pared to identify potential biomarkers for prostate can-
cer.
The goal of this study is to test the hypothesis that
glycomics might provide a marker on the presence or
absence of prostate cancer in patients who are utilizing
PSA. We chose to compare a group of men with no
prostate cancer and no prostate to one that had an intact
prostate with proven cancer undergoing active surveil-
lance because these groups provide the greatest degree
of separation in the samples. We believe that if we
could not find differences between these two groups,
then there is no way we would find differences between
closer subsets.
The comparison of these two groups gives no clini-
cal reason, but rather they are only used in this study
to determine feasibility of using glycomics analysis
to identify prognostic biomarkers. Our results show
glycan differences between the two groups: some
high-mannose glycans and acidic glycans were down-
regulated, while one fucosylated complex-type glycan
was up-regulated in the patient group. Future analy-
ses can focus on more relevant patient populations, e.g.
compare sera taken from post-prostatectomy men who
are monitored for disease recurrence and then corre-
late the glycan profile with progression-free survival
to determine the usefulness of the glycan profile as a
prognostic biomarker.
For rapid analysis, we chose to profile globally-
released N-linked oligosaccharides in these samples
without identifying the protein to which they had been
attached. Matrix-assisted laser desorption/ionization
Fourier transform-ion cyclotron resonance mass spec-
trometry (MALDI FT-ICR MS) was used to analyze
the N-linked glycans. MALDI MS provides a quick
method for profiling glycans and is comparatively toler-
ant to the presence of salts and other contaminants [26,
27]. The high resolution and high mass accuracy capa-
bilities of FT-ICR MS gives the glycan compositions,
i.e. the numbers of fucose, hexose, N-acetyhexosamine
and sialic acid [28].
2. Materials and methods
2.1. Human serum sample
Twenty serum samples from individuals with prostate
cancer (n = 10, under active surveillance for prostate
cancer, PSA = 5.4–27.0 ng/mL) and individuals with
their prostate removed (n = 10, post-radical retropubic
prostatectomy (post-RRP), PSA< 0.1 ng/mL) were ac-
quired from the University of California-Davis Medical
Center Clinical Laboratories using an IRB-approved
protocol. The serum samples were collected by stan-
dard venous phlebotomy into red top Vacutainer tubes
(or other standard clot-tubes) used for serum chemistry.
Samples were frozen at −80◦C until processing.
PSA testing was conducted by the UC Davis Medi-
cal Center Clinical Laboratory using the ADVIA Cen-
taur PSA assay test on a Bayer ADVIA Centaur (Bay-
er Diagnostics, Tarrytown, NY). Supplemental Table 1
shows the pathology characteristics of the twenty indi-
viduals from whom the serum samples were collected,
including the Gleason scores, PSA levels at draw and
current PSA, age, pathology stages, pathology margins
and pathology dates. The Pathology Stage is a clini-
cal assessment made by the urologist after performing
a digital rectal exam (DRE), obtaining a PSA level,
and receiving the pathology report from the patholo-
gist who analyzed the biopsy or radical prostatectomy
tissue. The Pathology Margin can only be assessed
after a radical prostatectomy as the entire prostate is
removed from the patient and the pathologist can de-
termine if the cancer went into the surgical margin or
if it stopped prior to reaching the margin. This has an
important bearing as to the higher risk of recurrence
for the margin-positive patients. A biopsy cannot be
assessed for margins as a biopsy only obtains small
samples of prostate tissue rather than the entire gland,
thus the patient group did not have pathology margin
data.
The individuals on active surveillance comprising the
patient group (P1–P10) were selected based on biopsy
proof of having prostate cancer and high PSA levels. It
was not possible to get the pathology staging for these
individuals as they only had biopsies, no RRPs. Their
pathology only indicates Gleason scores, not the extent
of cancer (staging) possible by the RRP.
The ten RRP patients comprising the control group,
on the other hand, were all stable with PSAs of < 0.1
and their pathology margins were all negative. These
were taken as evidence that they did not have active
prostate cancer.
2.2. pRNS cell lines
The pRNS-1-1 parental cell line is an SV40-
immortalized human prostate epithelial cell. pRNS-1-
1 cells were stably transfected with the empty vector,
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Fig. 1. Workflow of the analysis of N-linked glycans in serum and
cell line samples. N-linked glycans were released from denatured
glycoproteins by enzymatic digestion using PNGase F. Ethanol was
added to precipitate the proteins, leaving the glycans in the super-
natant. Fractionation and purification was done by solid phase extrac-
tion using graphitized carbon cartridges. Mass spectra were recorded
on a ProMALDI FT-ICR MS in six replicates per sample.
wild type androgen receptor (AR), the K580R AR mu-
tant or the T877A AR mutant. The development and
characterization of pRNS-1-1 and the pRNS-1-1 sub-
lines used in this study have been described extensively
elsewhere [29,30]. The parental pRNS-1-1 cells do not
express the AR or PSA [30]. The pRNS-1-1 sublines
were routinely maintained in RPMI 1640 supplement-
ed with 5% fetal bovine serum (FBS) and 50µg/mL
hygromycin. For glycan analysis, 1 × 106 cells were
plated in triplicate onto 100mm tissue culture dishes
and then grown for 3 days in RPMI 1640 supplemented
with 5% FBS prior to collection of the conditioned me-
dia. Samples were frozen at −80◦C until processing.
2.3. Enzymatic release of N-linked glycans
Figure 1 shows the flowchart for the analysis of N-
linked glycans in the samples. An aliquot of serum
or conditioned media from the cell lines (100 µL)
was mixed with 10 mM dithiothreitol (DTT, Promega,
Madison, WI) in 200 mM ammonium bicarbonate
(NH4HCO3, Sigma-Aldrich, St. Louis, MO) (100 µL)
and heated to 100◦C to denature the proteins.
The N-linked glycans were subsequently released
enzymatically using N-glycosidase F (PNGase F, New
England Biolabs, Ipswich, MA, 2.5 µL). The use of
PNGase F is advantageous since it releases glycans in
their original form, regardless of the glycans’ size or
structure [14]. PNGase F was added after cooling and
the mixture was incubated at 37◦C for 24 h in a water
bath.
Cold ethanol (800 µL) was added and the mixture
was frozen to −80◦C for 1 h to precipitate the pro-
teins. The N-linked glycans remained in solution (su-
pernatant) and were decanted and dried. The mixture
was then centrifuged for 20 min at 3200 rpm.
2.4. Glycan purification by solid phase extraction
The recovered supernatant was purified and fraction-
ated by solid phase extraction (SPE) using a graphi-
tized carbon cartridge (Alltech) eluting at increasing
concentrations of acetonitrile (ACN) in water. The car-
tridge was first conditioned with nanopure water, fol-
lowed by 0.05% (v/v) trifluoroacetic acid (TFA) in 80%
acetonitrile (ACN): water (v/v), and then by nanopure
water. The oligosaccharide solution was loaded onto
the cartridge and desalted with nanopure water (12 mL)
at a flow rate of about 1 mL/min. Glycans were eluted
with 10% ACN in H2O (v/v), 20% ACN in H2O (v/v),
and 40% ACN in 0.05% TFA in H2O (v/v). Neutral
oligosaccharides were eluted in the 10% and 20% ACN
fractions. The 40% ACN fraction contained 0.05%
TFA in its solvent to elute the acidic oligosaccharides.
Each fraction was collected and concentrated in vacuo
prior to mass spectrometry analysis.
2.5. Mass spectrometric analysis
Mass spectra were recorded on an FT-ICR MS with
an external source ProMALDI (Varian, Inc., Palo Alto,
CA) equipped with a 7.0 Tesla magnet. The ProMAL-
DI was equipped with a pulsed Nd:YAG laser (355 nm).
2,5-dihydroxy-benzoic acid (DHB) was used as a ma-
trix (5 mg/100 µL in 50% ACN:H2O) for both posi-
tive and negative modes. A saturated solution of NaCl
in 50% ACN: H2O was used as a cation dopant. The
oligosaccharide solution (0.5 µL) was applied to the
MALDI probe followed by matrix solution (0.5 µL).
The sample was dried under vacuum prior to mass spec-
trometric analysis. Two MALDI spots were prepared
per sample, and each spot was divided into three: the
upper, middle and lower spots. A spectrum was ob-
tained for each of the three divisions, giving a total
of six mass spectral acquisitions per sample. Tandem
mass spectrometry using collision-induced dissociation
was performed to confirm some of the N-linked glycan
compositions.
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2.6. Data analysis
Six mass spectral acquisitions per sample were done
on the 10%, 20% and 40% aqueous acetonitrile (ACN)
fractions. All spectra were calibrated prior to data
analysis using Omega (Ionspec) software. Analysis
of the data was performed using in-house programs
written in Igor Pro (Wavemetrics).
The mass spectral peaks for each sample were
checked against an in-house N-linked glycan library
based on accurate mass. The resulting list of N-linked
glycans was further filtered based on the following cri-
teria: the peaks should be detected in at least 70% of the
spectra, with at least 1% intensity, and with intensity
changes of at least 20% between the two groups.
For the comparison of the peaks in the patient
and normal samples, statistical analysis using one-way
analysis of variance (ANOVA) was performed. If the
p-value was less than 0.05, the difference between the
two groups was considered statistically significant.
3. Results and discussion
3.1. Repeatability of the method
Repeatability is the agreement of individual test re-
sults when the method is applied repetitively. The twen-
ty human serum samples were used to test the repeata-
bility of the method. Six mass spectral acquisitions per
sample were obtained consecutively in one laboratory
session. The number of N-glycans generated for each
spectrum was counted and the relative standard devia-
tions were computed. Figure 2 shows the graph of the
glycan peaks generated from the 10% and 20% ACN
fractions. The relative standard deviations (RSDs) for
the 10% ACN fraction ranged from 2.4 to 12.4%, with
a mean value of 7.7%. For the 20% ACN fraction, the
RSDs ranged from 4.7 to 14.7%, with a mean value
of 7.9%. More variation was seen in the 40% ACN
fraction, indicating that acidic species are less stable
than the neutral glycans during the MALDI analysis.
The 40% ACN fraction gave an RSD range of 3.5%
to 23.3% and a mean value of 12.6% (Supplementary
Fig. 1).
3.2. N-linked glycans in prostate epithelial cell lines
This method was first performed on prostate epithe-
lial cell lines to demonstrate the application of N-linked
glycans and MS analysis for prostate cancer biomarker
analysis. The cell lines used were pRNS1-1, an ep-
ithelial immortalized prostate cell line, and sub-lines
of pRNS1-1 cells that had been stably transfected with
the wild type androgen receptor gene or with two sep-
arate mutants of the androgen receptor (AR). The AR
is a transcription factor that plays a key role in con-
trolling proliferation, differentiation and morphogene-
sis in the prostate gland. In the normal prostate, the
AR is activated by circulating androgen. A common
finding in advanced prostate cancer is that other fac-
tors besides androgen, e.g. other steroid hormones and
anti-androgens [31], can cause activation of the AR.
The consequence of this aberrant activation is that an-
drogen ablation, one of the primary treatments for re-
current metastatic prostate cancer, quickly becomes in-
effective and the disease progresses to androgen inde-
pendent (AI) prostate cancer. This advanced form of
prostate cancer is incurable. The ability of the AR to
be activated by factors other than androgen has been
linked to certain AR mutations [29,32]. It has been
documented that androgen receptor mutations occur at
a frequency of 27% to 50% in advanced prostate can-
cer [33–35]. Approximately 60 different AR mutations
have been described in prostate cancer patients (see
http://www.mcgill.ca/androgendb). Hot spot mutations
include K580R (located close to the boundary of the
hinge and ligand-binding domains) and T877A (locat-
ed in the primary binding site for p160 co-activators).
We are determining if the presence of the AR muta-
tions causes significant glycosylation changes in these
cells that can be detected in their conditioned media.
This approach is based on the idea that glycosylation
of proteins is altered in tumor cells and contribute to
the tumorigenesis of the pRNS1-1 sublines that contain
the AR mutants. The glycosylation changes can be
detected in the conditioned media of these cells just as
they might be detected in the serum of prostate cancer
patients.
The pRNS-1-1 cell line is an immortalized non-
tumorigenic androgen dependent prostate cell line that
at late passages does not express AR. The sublines as-
sessed in this study were late passage pRNS-1-1 sta-
bly transfected with an empty vector control, wild type
(WT) AR, and the ARK580R or ART877A mutant al-
leles. Previous studies have determined that transfec-
tion of pRNS-1-1 with the ARK580R or ART877A al-
leles promotes androgen independent (AI) growth of
pRNS-1-1 both in vitro and in vivo, i.e. a phenotype
associated with advanced prostate cancer [29]. Soft
colony agar assays have also been used to demonstrate
that transfection of pRNS-1-1 with either the K580R or
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Fig. 2. Number of glycan peaks found in the 10% and 20% acetonitrile fractions. Six spectral acquisitions were done for each sample and the
relative standard deviations were computed. The relative standard deviations (RSDs) for the 10% ACN fraction ranged from 2.4 to 12.4%, with
a mean value of 7.7% (Fig. 2A) and for the 20% ACN fraction, the RSDs ranged from 4.7 to 14.7%, with a mean value of 7.9% (Fig. 2B). Bars
for standard deviation of the mean are shown for six replicates.
T877A AR mutations results in anchorage-independent
growth [29], a growth characteristic that is associat-
ed with cancer cells. pRNS-1-1 transfected with emp-
ty vector or WT AR was unable to cause androgen-
independent or anchorage-independent growth. In
these studies, RNA interference analysis was used to
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Positive MALDI-FTMS Spectra of pRNS 20% ACN Fractions
Fig. 3. Comparison of mass spectra of pRNS1-1 samples. (A) MALDI-FTICR MS spectra acquired in the positive mode of the 20% ACN
fraction of cell culture media (media); pRNS cell line with vector alone; pRNS cell line with wild type (WT) androgen receptor (AR); pRNS
with the K580R AR mutant (AR580); pRNS1-1 with T877A AR mutant (AR877). (B) Zoom-in on the (B-1) wildtype (WT) and (B-2) AR580.
AR877 contains the high-mannose glycans seen in AR580, but major signals correspond to non-glycan peaks. (C) MALDI-FTICR MS spectra
acquired in the negative mode of the 40% ACN fraction from the pRNS1-1 cell lines. Symbol representations of glycans for this figure: GlcNAc,
filled square (); HexNAc, hollow square (); Man, filled circle (•); Hex, hollow circle (©); NeuAc, filled diamond (). GlcNAc =
N-acetylglucosamine; HexNAc = N-acetylhexosamine; Man = mannose; Hex = hexose; NeuAc = neuraminic acid or sialic acid.∗non-glycan
peaks
confirm that these growth characteristics were due to
the presence of mutant AR. In vivo experiments con-
firmed the ability of the pRNS-1-1 cells containing the
mutant AR constructs to form tumors in nude mice.
Figure 3A shows the representative spectra of the
20% ACN fractions of the medium, vector, wild type
(WT), AR580 (K380R) and AR877 (T877A) obtained
in the positive mode of the MALDI FT-ICR MS. Cell
culture media (10% FBS in RPMI1640) was analyzed
as a control. Majority of the glycans were observed in
20% and 40% ACN fractions. Significant changes in N-
linked glycans were observed in the 20% ACN fraction
(Fig. 3A) while the 40% ACN fraction contained the
same bovine serum oligosaccharides (Fig. 3C). High
mannose N-linked glycans were identified in the mu-
tant samples (Fig. 3B) but not in the medium, vector,
or WT samples, suggesting that the increased presence
of high mannose N-linked glycans may be an indicator
for tumorigenesis of these cell lines. Analysis of spec-
tra from the 40% ACN fractions (Fig. 3C) showed the
presence of complex N-linked oligosaccharides in these
samples, but no significant difference was detected be-
tween these samples. The same glycans were detect-
ed in samples of the culture media indicating that they
most likely originated from serum proteins of the fetal
bovine serum added to the RPMI cell culture medium.
3.3. Profile of N-linked glycans in human sera
We next analyzed a small set of serum samples
comparing 10 samples from individuals with low PSA
values (< 0.1 ng/mL) and had undergone RRP with
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no evidence of active disease (control group) and 10
samples from patients with elevated PSA values (5.4-
27.0 ng/mL) who were on active surveillance (patient
group). Figure 4 shows the representative spectra of
the 10, 20 and 40% ACN fractions from the patient
group. In the low mass region of the 10% ACN spectra
acquired in the positive mode, the N-linked glycans are
primarily neutral glycans, mostly high-mannose and
complex-type glycans with or without fucose. The
20% ACN fraction contains both the neutral and acidic
glycans, thus spectra in both positive and negative ion
modes were collected. The acidic glycans, i.e. glycans
with at least one sialic acid, elute in the 40% ACN
fraction and are detected in the negative mode.
The overall profile of the abundant glycans is the
same for the patient and control groups. When re-
gions of low-intensity masses are amplified, more gly-
cans are observed and the differences between the two
groups become more apparent. For instance, Figure 5
shows a bar graph of the 20% ACN fraction showing
the mass-to-charge ratio (m/z) versus the absolute in-
tensity. The graph shows the m/z values in decreas-
ing intensity. The trend of the peaks for both patient
and control groups is quite similar: the most abundant
glycan for both groups is m/z 1647.586, followed by
m/z 1809.639,m/z 1485.534 and m/z 1663.581.
Glycan compositions were determined by exact
masses obtained from high-resolution mass spectrom-
etry with less than 10 ppm error tolerance. Tandem
mass spectrometry using collision-induced dissocia-
tion was further performed to confirm the N-linked
glycan compositions. Figure 6 shows an example of
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Fig. 3, continued.
an MS/MS spectrum, with m/z 1809.639 consisting
of 5Hex, 4HexNAc, and 1Fuc, and the corresponding
monosaccharide losses.
3.4. Data analyses on the N-linked glycans in human
sera
Based on the set criteria (i.e. peaks should be detect-
ed in at least 70% of the spectra, with at least 1% inten-
sity and with intensity changes of at least 20% between
the two groups), 24 peaks from the three ACN fractions
were obtained (16 neutral glycans and 8 acidic glycans),
as shown in Supplemental Table 2. The glycan peaks
that were different in the patient and control groups
were predominantly high mannose (Man5-Man9, 5-
9Hex: 2HexNAc) and neutral complex-type glycans in
the 10% and 20% ACN fractions. For the 40% ACN
fraction, the glycan peaks identified were mostly sia-
lylated. Fourteen glycans were down-regulated in the
patient group while ten were up-regulated. Except for
the Man5 glycan (m/z 1257.423), all the identified
high-mannose peaks were down-regulated in the pa-
tient group. The up-regulation of Man5 in the patient
group is consistent with the pRNS cell line observation
that Man5 was seen in the mutant samples but not in
the medium, vector or wild-type samples. The down-
regulation of the other high-mannose glycans did not
agree with the pRNS cell line results, which showed an
up-regulation of the high-mannose glycans in the mu-
tant species. Thus, we find no correlation between the
pRNS cell lines and the serum data, which is consis-
tent with the results of Tabares et al. [3]: the cell lines
indeed might not be indicative of the actual physiolog-
ical conditions. Serum is a more complicated glyco-
protein mixture and the overall down-regulation of the
high mannose glycans may be due to many contribut-
ing factors. Aberration in glycosylation may include
not just a few low abundance proteins, but potentially
every single glycoprotein from a diseased cell.
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Fig. 4. Representative MALDI FT-ICR mass spectra of N-linked glycans in patient and control sera proteins from the acetonitrile (ACN) fractions
analyzed in the positive (+) and negative (−) ion modes. The spectra came from one prostate cancer patient sample. Structures are putative and
are based on accurate mass.
However, we find that our results on the down-
regulation of the high mannose glycans in the human
sera of prostate cancer patients are consistent with
Novotny’s results [24] even if the sample set is differ-
ent. Our control group are individuals who underwent
prostatectomy (post-RRP), i.e. they had their prostate
removed.
Eleven fucosylated N-linked glycans were changing
between the two groups: six were down-regulated and
five were up-regulated in the patient group. The eight
sialylated (acidic) glycans are mostly up-regulated in
the patient group, except for two: m/z 2295.813 and
m/z 2568.884. The twelve neutral complex-type gly-
cans were mostly down-regulated in the patient group
except for five glycans.
T-tests were then performed and a p-value was ob-
tained for each peak. A p-value of 0.05 or lower was
considered statistically significant. The peaks were re-
duced to seven and are shown in Table 1. Of the sev-
en N-linked glycans, six are down-regulated in the pa-
tient group. All the four identified glycans in the 10%
ACN fraction are high-mannose-type glycans (hexose
= 6–9) and the two glycans observed in the 20% ACN
fraction are either fucosylated or sialylated complex-
type glycans differing by one hexose (4:4:1:0, 5:4:0:1
Hex:HexNAc:Fuc:NeuAc). The said acidic (sialylated)
glycan (5:4:0:1) is the only up-regulated marker found
among the seven potential markers. For the 40% ACN
fraction, only one N-glycan was significantly changing
between the control and patient group, and this gly-
can is both sialylated and fucosylated (m/z 2568.884,
7Hex:4HexNAc:2Fuc:1NeuAc). The two fucosylated
glycans (4:4:1:0 and 7:4:2:1) were both down-regulated
in the patient group, consistent with Llorens’ results [3]
in the fucosylation of PSA from the prostate cancer
patient serum. Figure 7 shows a bar graph of absolute
intensities of the seven identified N-linked glycans.
4. Summary
An MS-based method to analyze the N-linked gly-
cans in human sera is being developed. This pilot study
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N- Linked Glly cans in Pat ient and Co nt r o l Gr o up s in t he 2 0 % A CN Fr ac t ion
m/ z Composit ion* * *
[ M+Na]+
1647.586 12473.12 – 1219.91 18370.59 – 2371.84 4:4 :1 :0
1809.639 6480.37 – 594.65 9076.00 – 1525.67 5:4 :1 :0
1485.534 5615.43 – 793.16 8942.20 – 1331.72 3:4 :1 :0
1663.581 2620.38 – 298.92 1992.19 – 342.43 5:4 :0 :0
1444.507 1487.03 – 93.92 1665.08 – 171.95 4:3 :1 :0
1282.454 1280.02 – 172.64 1738.36 – 224.58 3:3 :1 :0
1501.529 1157.34 – 79.79 1315.78 – 149.08 4:4 :0 :0
*Six acquisitions per sample; **Intensity errors reported as standard deviations of the mean
***Glycan compositions based on accurate mass by MALDI-FTICR MS.
Absolut e Int ensit ies and Gllycan Composit ion of t he First 7 Peaks
PATIENT (n=10* ) CONTROL (n=10* )
Absolut e Int ensit y* * Absolut e Int ensit y* *
Hexose N-acetylhexosamine Deoxyhexose Sialic Acid
: : :
Fig. 5. Profile of N-linked glycans in the 20% ACN fraction of the serum samples acquired in the positive mode. The m/z values are arranged in
order of decreasing absolute intensity. The trend is similar for both the patient and control groups. Bars for standard deviation of the mean are
shown for six replicates.
Table 1
The seven possible N-linked glycan biomarkers that are statistically significant (p < 0.05) from the three ACN fractions
of the serum samples. Glycan compositions are based on the accurate mass as determined by MALDI-FTICR MS.
m/z Composition∗ CONTROL (n = 10∗∗) PATIENT (n = 10∗∗) p-value
[M + Na]+ © :  :  : ♦ Absolute Intensity∗∗∗ Absolute Intensity∗∗∗
10% ACN Fraction
1419.475 6:2:0:0 1884.66 ± 249.91 1055.98 ± 195.10 0.018
1581.528 7:2:0:0 539.73 ± 73.59 286.05 ± 41.22 0.008
1743.581 8:2:0:0 933.97 ± 119.38 495.40 ± 63.45 0.005
1905.634 9:2:0:0 686.63 ± 149.63 269.58 ± 26.63 0.014
20% ACN Fraction
1647.586 4:4:1:0 23281.62 ± 3648.92 15047.75 ± 1262.07 0.047
1976.659 5:4:0:1 752.71 ± 140.70 1280.81 ± 192.75 0.040
40% ACN Fraction
2568.884 7:4:2:1 139.87 ± 12.01 106.49 ± 6.33 0.024
∗Glycan compositions based on accurate mass by MALDI-FTICR MS.
©Hexose: N-Acetylglucosamine: Fucose: ♦Sialic Acid
∗∗Six acquisitions per sample
∗∗∗Absolute intensity errors reported as standard deviation of the mean
may be useful for future studies since we observed in-
tensity differences in the N-linked glycans between the
patient and control groups. Seven potential N-linked
glycan biomarkers were identified from the three SPE
fractions. These were mostly high mannose type N-
linked glycans.
Four high-mannose (Man6-Man9) type, one neu-
tral and one acidic complex-type glycans are down-
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Fig. 6. Collision-induced dissociation of a fucosylated biantennary N-linked glycan with m/z 1809.639. The monosaccharide losses based on
accurate mass are shown.
Potential N-linked Glycan 
0
5000
10000
15000
20000
25000
1419.475 1581.528 1743.581 1905.634 1647.586 1976.659 2568.884
m/z
Control Group (n=10)
Patient Group (n=10)
Fig. 7. Graph of absolute intensities of the seven potential N-linked glycan biomarkers that are statistically different (p < 0.05) from the control
(post-radical retropubic prostatectomy) and patient (under active surveillance) groups. All peaks from the three ACN fractions of the serum
samples are down-regulated in the patient group except for one (m/z 1977). Bars for standard deviation of the mean are shown for six replicates.
regulated in the patient group while one acidic
complex-type glycan is up-regulated in the patient
group with active disease (under active surveillance).
These glycan changes are significantly different from
individuals without active disease after having under-
gone RRP.
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Although further testing and validation of these find-
ings are necessary for future studies, the results suggest
that it is possible to use glycomics as a method to obtain
potential markers for prostate cancer. To further prove
the utility of glycomics in this case, a bigger sample set
may be necessary, possibly consisting of a) men with
normal prostates, b) men with BPH, c) men who have
localized prostate cancer, d) men who have elevated
and e) lowered PSAs after radical prostatectomies and
f) men who have metastatic disease prior to and g) after
initiation of hormonal therapy. A big undertaking such
as this is warranted given the positive results presented
in this study. Moreover, the collection of blood sam-
ples from these individuals should be time-controlled
in subsequent studies, to avoid variation due to physical
trauma or inflammation following surgery.
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ACN: acetonitrile
BPH: benign prostate hyperplasia
IRMPD: infrared multiphoton dissociation
MALDI FT-ICR MS: matrix-assisted laser desorp-
tion/ioniz-ation-Fourier transform ion-cyclotron reso-
nance mass spectrometry (or spectrometer)
PNGase F: peptideN -glycosidase F from Flavobac-
terium meningosepticum
PSA: prostate-specific antigen
RRP: radical retropubic prostatectomy
RSD: relative standard deviation
TFA: trifluoroacetic acid
References
[1] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M.J.
Thun, Cancer Statistics, CA: a cancer Journal for Clinicians,
2008.
[2] National-Cancer-Institute, What You Need to Know About
Prostate Cancer, 2005.
[3] G. Tabares, C.M. Radcliffe, S. Barrabes, M. Ramirez, R.N.
Aleixandre, W. Hoesel, R.A. Dwek, P.M. Rudd, R. Peracaula
and R.d. Llorens, Different Glycan Structures in Prostate-
specific Antigen from Prostate Cancer Sera in Relation to
Seminal Plasma PSA, Glycobiology 16 (2006), 132–145.
[4] C. Stephan, K. Jung, M. Lein and E.P. Diamandis, PSA and
Other Tissue Kallikreins for Prostate Cancer Detection, Euro-
pean Journal of Cancer 43 (2007), 1918–1926.
[5] R. Peracaula, G. Tabares, L. Royle, D.J. Harvey, R.A. Dwek,
P.M. Rudd and R.d. Llorens, Altered Glycosylation Pattern Al-
lows the Distinction between Prostate-specific Antigen (PSA)
from Normal and Tumor Origins, Glycobiology 13 (2003),
457–470.
[6] I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen,
M.S. Lucia, H.L. Parnes, L.M. Minasian, L.G. Ford, S.M.
Lippman, E.D. Crawford, J.J. Crowley and C.A. Jr. Coltman,
Prevalence of prostate cancer among men with a prostate-
specific antigen level < or = 4.0 ng per milliliter, The New
England journal of medicine 350 (2004), 2239–2246.
[7] D.J. Parekh, D.P. Ankerst, D. Troyer, S. Srivastava and I.M.
Thompson, Biomarkers for prostate cancer detection, J Urol
178 (2007), 2252–2259.
[8] O.P. Bondar, D.R. Barnidge, E.W. Klee, B.J. Davis and
G.G. Klee, LC-MS/MS Quantification of Zn-α2 Glycoprotein:
A Potential Serum Biomarker for Prostate Cancer, Clinical
Chemistry 53 (2007), 673–678.
[9] D. Maraldo, F.U. Garcia and R. Mtharasan, Method for Quan-
tification of a Prostate Cancer Biomarker in Urine without
Sample Preparation, Analytical Chemistry 79 (2007), 7683–
7690.
[10] B. Matharoo-Ball, G. Ball and R. Rees, Clinical Proteomics:
Discovery of Cancer Biomarkers using Mass Spectrometry
and Bioinformatics Approaches–A Prostate Cancer Perspec-
tive, Vaccine 25S (2007), B110–B121.
[11] M. Hellstrom, S. Jonmarker, J. Lehtio, G. Auer and L. Egevad,
Proteomics in Clinical Prostate Research, Proteomics: Clini-
cal Applications 1 (2007), 1058–1065.
[12] M.W. Datta, L.D. True, P.S. Nelson and M.B. Amin, The Role
of Tissue Microarrays in Prostate Cancer Biomarker Discov-
ery, Advances in Anatomic Pathology 14 (2007), 408–418.
[13] G. Sardana, J. Marshall and E.P. Diamandis, Discovery of
Candidate Tumor Markers for Prostate Cancer via Proteom-
ic Analysis of Cell Culture-Conditioned Medium, Clinical
Chemistry 53 (2007), 429–437.
[14] Y. Kita, Y. Miura, J.-I. Furukawa, M. Nakano, U. Shinohara,
M. Ohno, A. Takimoto and S.-I. Nishimura, Quantitative Gly-
comics of Human Whole Serum Glycoproteins Based on the
Standardized Protocol for Liberating N-Glycans, Molecular
and Cellular Proteomics 6 (2007), 1437–1445.
[15] S. Hakomori, Glycosylation Defining Cancer Malignancy:
New Wine in an Old Bottle, Proceedings of the National
Academy of Sciences of the United States of America 99
(2002), 10231–10233.
[16] T.-Y. Chou and G.W. Hart, O-linked N-acetylglucosamine and
Cancer: Messages from the Glycosylation of C-Myc, Ad-
vances in Experimental Medicine and Biology 491 (2001),
413–418.
256 M.L.A. de Leoz et al. / Glycomic approach for potential biomarkers on prostate cancer
[17] M.A. Hollingsworth and B.J. Swanson, Mucins in cancer:
protection and control of the cell surface, Nature reviews 4
(2004), 45–60.
[18] H.F. Valenzuela, K.E. Pace, P.V. Cabrera, R. White, K. Porvari,
H. Kaija, P. Vihko and L.G. Baum, O-Glycosylation Regulates
LNCaP Prostate Cancer Cell Susceptibility to Apoptosis In-
duced by Galectin-1, Cancer Research 67 (2007), 6155–6162.
[19] R.A. Dwek, Glycobiology: Toward Understanding the Func-
tion of Sugars, Chemical Reviews 96 (1996), 683–720.
[20] D.J. Harvey, Proteomic Analysis of Glycosylation: Structural
Determination of N- and O-linked Glycans by Mass Spec-
trometry, Expert Review of Proteomics 2 (2005), 87–101.
[21] A. Kobata and J. Amano, Altered Glycosylation of Proteins
Produced by Malignant Cells, and Application for the Diag-
nosis and Immunotherapy of Tumours, Immunology and Cell
Biology 83 (2005), 429–439.
[22] H.J. An, S. Miyamoto, K.S. Lancester, C. Kirmiz, B. Li, K.S.
Lam, G.S. Leiserowitz and C.B. Lebrilla, Profiling of Glycans
in Serum for the Discovery of Potential Biomarkers for Ovar-
ian Cancer, Journal of Proteome Research 5 (2006), 1626–
1635.
[23] C. Kirmiz, B. Li, H.J. An, B.H. Clowers, H.K. Chew, K.S.
Lam, A. Ferrige, R. Alecio, A.D. Borowsky, S. Sulaimon,
C.B. Lebrilla and S. Miyamoto, A Serum Glycomics Ap-
proach to Breast Cancer Biomarkers, Molecular and Cellular
Proteomics 6 (2007), 43–55.
[24] Z. Kyselova, Y. Mechref, M.M. Al Bataineh, L.E. Dobrolec-
ki, R.J. Hickey, J. Vinson, C.J. Sweeney and M.V. Novotny,
Alterations in the serum glycome due to metastatic prostate
cancer, J Proteome Res 6 (2007), 1822–1832.
[25] T. Fujimura, Y. Shinohara, B. Tissot, P.-C. Pang, M. Kuro-
gochi, S. Saito, Y. Arai, M. Sadilek, K. Murayama, A. Dell,
S.-I. Nishimura and S.-I. Hakomori, Glycosylation Status of
Haptoglobin in Sera of Patients with Prostate Cancer vs. Be-
nign Prostate Disease or Normal Subjects, Int J Cancer 122
(2008), 39–49.
[26] D.J. Harvey, Structural determination of N-linked glycans by
matrix-assisted laser desorption/ionization and electrospray
ionization mass spectrometry, Proteomics 5 (2005), 1774–
1786.
[27] J. Zaia, Mass spectrometry of oligosaccharides, Mass spec-
trometry reviews 23 (2004), 161–227.
[28] Y. Park and C.B. Lebrilla, Application of Fourier transform ion
cyclotron resonance mass spectrometry to oligosaccharides,
Mass spectrometry reviews 24 (2005), 232–264.
[29] X.-B. Shi, X. Lingru, C.G. Tepper, R. Gandour-Edwards, P.
Ghosh, H.-J. Kung and R.W.d.V. White, The Oncogenic Po-
tential of a Prostate Cancer-derived Androgen Receptor Mu-
tant, Prostate 67 (2007), 591–602.
[30] M.S. Lee, E. Garkovenko, J.S. Yun, P.C. Weijerman, D.M.
Peehl, L.S. Chen and J.S. Rhim, Characterization of Adult
Human Prostatic Epithelial Cells Immortalized by Polybrene-
induced DNA Transfection with a Plasmid Containing an
Origin-defective SV40 Genome, Int J Oncol 4 (1994), 821–
830.
[31] J. Veldsholte, C.A. Berrevoets, C. Ris-Stalpers, G.G.J.M.
Kuiper, G. Jenster, J. Trapman, A.O. Brinkmann and E. Mul-
der, The Androgen Receptor in LNCaP Cells Contains a Mu-
tation in the Ligand Binding Domain Which Affects Steroid
Binding Characteristics and Response to Antiandrogens, Jour-
nal of Steroid Biochemistry and Molecular Biology 41 (1992),
665–669.
[32] G. Han, G. Buchanan, M. Ittmann, J.M. Harris, X. Yu, F.J.
DeMayo, W. Tilley and N.M. Greenberg, Mutation of the
Androgen Receptor Causes Oncogenic Transformation of the
Prostate, Proceedings of the National Academy of Sciences of
the United States of America 102 (2005), 1151–1156.
[33] M. Marcelli, M. Ittmann, S. Mariani, R. Sutherland, R. Nigam,
L. Murthy, Y. Zhao, D. DiConcini, E. Puxeddu, A. Esen, J.
Eastham, N.L. Weigel and D.J. Lamb, Androgen Receptor
Mutations in Prostate Cancer, Cancer Research 60 (2000),
944–949.
[34] M.-E. Taplin, G.J. Bubley, T.D. Shuster, M.E. Frantz, A.E.
Spooner, G.K. Ogata, H.N. Keer and S.P. Balk, Mutation of the
Androgen-receptor Gene in Metastatic Androgen-independent
Prostate Cancer, New England Journal of Medicine 332
(1995), 1393–1398.
[35] W.D. Tilley, G. Buchanan, T.E. Hickey and J.M. Bentel, Mu-
tations in the Androgen Receptor Gene are Associated with
Progression of Human Prostate Cancer to Androgen Indepen-
dence Clinical Cancer Research 2 (1996), 277–285.
M.L.A. de Leoz et al. / Glycomic approach for potential biomarkers on prostate cancer 257
Supplemental Table 1
Pathology information of the individuals in the control (C1-C10) and patient (P1–P10) groups of the serum
samples. AS = active surveillance; RRP = radical retropubic prostatectomy
Lab Gleason PSA at Draw Last PSA Age Treatment Pathology Pathology Pathology
Code Score (ng/mL) (ng/mL) Stage Margins Date
P1 6 10.9 16.79 75 AS ∗ ∗ 11/1/04
P2 6 7.7 6.1 66 AS ∗ ∗ 6/1/05
P3 5 7.9 11.2 65 AS ∗ ∗ 5/23/05
P4 6 5.4 8.5 80 AS ∗ ∗ 8/25/05
P5 6 27 21.6 71 AS ∗ ∗ 8/15/05
P7 6 5.9 6.3 53 AS ∗ ∗ 10/6/05
P6 6 5.7 6.4 66 AS ∗ ∗ 10/5/05
P8 6 7 8.7 71 AS ∗ ∗ 10/20/05
P9 6 5.8 4.9 63 AS ∗ ∗ 11/1/05
P10 6 12.2 10.9 81 AS ∗ ∗ 11/9/05
N1 7 <0.1 <0.1 72 RRP pT2a Negative 1/9/06
N2 7 <0.1 <0.1 69 RRP pT2b Negative 1/19/06
N3 7 <0.1 <0.1 54 RRP pT2a Negative 2/2/06
N4 6 <0.1 <0.1 53 RRP pT2b Negative 3/6/06
N5 7 <0.1 <0.1 59 RRP pT2c Negative 4/10/06
N6 6 <0.1 <0.1 61 RRP pT2b Negative 4/24/06
N7 6 <0.1 <0.1 62 RRP pT1c Negative 4/28/06
N8 7 <0.1 <0.1 56 RRP pT2c Negative 6/5/06
N9 7 <0.1 <0.1 58 RRP pT3a Negative 6/5/06
N10 7 <0.1 <0.1 57 RRP pT3a Negative 6/6/06
∗Active surveillance patients not pathologically staged (biospy only).
Supplemental Table 2
Filtered glycan peaks based on the set criteria on abundance, frequency and delta for the three ACN fractions
using MALDI FT-ICR MS. The m/z values shown in bold are significantly changing between the two
groups based on t-test (p-value < 0.05) The glycan composition is based on accurate mass.
m/z Composition∗ CONTROL (n = 10∗∗) PATIENT (n = 10∗∗) p-value
[M + Na]+ © :  :  : ♦ Absolute Intensity∗∗∗ Absolute Intensity∗∗∗
Filtered Peaks in the 10% ACN Fraction
1257.423 5:2:0:0 869.46 ± 96.92 1100.88 ± 152.84 0.217
1419.475 6:2:0:0 1884.66 ± 249.91 1055.98 ± 195.10 0.018
1581.528 7:2:0:0 539.73 ± 73.59 286.05 ± 41.22 0.008
1622.555 6:3:0:0 701.23 ± 128.52 440.75 ± 63.77 0.086
1663.581 5:4:0:0 1221.28 ± 139.51 1508.57 ± 299.23 0.396
1743.581 8:2:0:0 933.97 ± 119.38 495.40 ± 63.45 0.005
1825.634 6:4:0:0 275.27 ± 42.71 179.18 ± 28.26 0.085
1905.634 9:2:0:0 686.63 ± 149.63 269.58 ± 26.63 0.014
Filtered Peaks in the 20% ACN Fraction
1282.454 3:3:1:0 1899.38 ± 368.99 1450.04 ± 166.54 0.282
1339.476 3:4:0:0 648.16 ± 143.87 484.04 ± 43.40 0.289
1485.534 3:4:1:0 10573.93 ± 1799.03 6581.71 ± 858.37 0.060
1647.586 4:4:1:0 23281.62 ± 3648.92 15047.75 ± 1262.07 0.047
1663.581 5:4:0:0 2673.90 ± 535.23 3234.04 ± 341.47 0.389
1809.639 5:4:1:0 12619.49 ± 3112.12 8047.16 ± 702.73 0.169
1976.659 5:4:0:1 752.71 ± 140.70 1280.81 ± 192.75 0.040
Filtered Peaks in the 40% ACN Fraction
2082.725 4:4:2:1 409.80 ± 55.70 517.12 ± 42.53 0.143
2084.717 9:3:0:0 199.23 ± 23.29 252.08 ± 26.24 0.149
2295.813 6:5:0:1 1231.82 ± 127.72 943.51 ± 86.20 0.078
2296.833 6:5:2:0 1204.20 ± 121.10 928.00 ± 81.98 0.075
2389.816 5:4:1:2 244.88 ± 19.34 295.84 ± 28.07 0.152
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Supplemental Table 2, continued
m/z Composition∗ CONTROL (n = 10∗∗) PATIENT (n = 10∗∗) p-value
[M + Na]+ © :  :  : ♦ Absolute Intensity∗∗∗ Absolute Intensity∗∗∗
2390.836 5:4:3:1 251.69 ± 16.79 313.49 ± 30.85 0.096
2568.884 7:4:2:1 139.87 ± 12.01 106.49 ± 6.33 0.024
2754.948 6:5:1:2 115.14 ± 9.21 147.16 ± 18.51 0.139
2755.968 6:5:3:1 124.51 ± 11.41 173.80 ± 22.40 0.066
∗Glycan compositions based on accurate mass by MALDI-FTICR MS.
©Hexose: N-Acetylglucosamine: Fucose: ♦Sialic Acid.
∗∗Six acquisitions per sample.
∗∗∗Absolute intensity errors reported as standard deviation of the mean.
Glycan Peaks Found in the 40% ACN Fraction
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Supplementary Fig. 1. Number of glycan peaks found in the 40% ACN fractions. Six spectral acquisitions were done for each sample and the
relative standard deviations were computed. The RSDs ranged from 3.5% to 23.3% and a mean value for 12.6%. Bars for standard deviation
of the mean are shown for six replicates.
